论文部分内容阅读
用ＥＬＩＳＡ方法测定了３０例肝癌患者血清可溶性肿瘤坏死因子受体Ⅰ（ｓＴＮＦＲ－Ⅰ）水平。结果表明，肝癌患者血清ｓＴＮＦＲ－Ⅰ水平明显高于正常人（ｐ＜０．０１），且血清ｓＴＮＦＲ－Ⅰ水平与临床分期相关。治疗有效者，血清ｓＴＮＦＲ－１水平均明显下降（ｐ＜０．０１）．治疗后２～８月，３例无癌生存者，血清ｓＴＮＦＲ－１水平降至正常，而７例局部未控或复发转移者，血清ｓＴＮＦＲ－１水平则进行性上升。提示，血清ｓＴＮｌＦＲ－Ⅰ测定对肝癌患者的诊断、疗效观察及预后判断可能有一定的参考价值。
Serum levels of soluble tumor necrosis factor receptor I (sTNFR-I) in 30 patients with hepatocellular carcinoma were measured by ELISA. The results showed that serum sTNFR-I levels were significantly higher in patients with hepatocellular carcinoma than in normal subjects (p<0.01), and serum sTNFR-I levels were associated with clinical stage. With effective treatment, serum sTNFR-1 levels decreased significantly (p<0.01). From 2 to 8 months after treatment, serum sTNFR-1 levels were reduced to normal in 3 cases of cancer-free survival, whereas serum sTNFR-1 levels were progressively increased in 7 patients with uncontrolled or recurrent metastases. It is suggested that serum sTNlFR-I assay may have certain reference value for the diagnosis, curative effect observation and prognosis judgment of liver cancer patients.